Joint Formulary & PAD

Mepolizumab - Eosinophilic COPD

You are here : Home > Formulary Search > Mepolizumab - Eosinophilic COPD

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative
Formulations :

No records returned.

Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
NICE
SPC
Restrictions / Comments :

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Mepolizumab
Indication :
Eosinophilic COPD
Group Name :
Keywords :
Brand Names Include :
Nucala
Important Information :

This drug for this condition has not been assessed or agreed for inclusion on the formulary. Refer to pharmacy for advice.

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Committee Recommendations (1)

04 Feb 26 - Not Set

This drug has not yet been assessed for formulary status.
It has not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing, it is recommended that clinicians contact their Pharmacy / Medicines Optimisation team to discuss possible alternatives/options.

NICE are due to publish guidance on this drug in August 2026 and this will be considered by the APC within 90 days of publication.

Other Indications

Below are listed other indications that Mepolizumab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Eosinophilic COPD.

  • No records returned.